prr thursday, page-16

"We expect that interim data, if any, could be available
within a year of first dose, that is, around July 2011"

That was taken from an analyst research piece Mugtrader, not a PRR announcement. A bit unfair to blame the company for what someone else said.

LOL no need to call anyone at PRR about interim results, they're busy doing what they should be doing.



Extract from March newsletter re Phase IIb Trials

"Patient enrollment into the randomised component of the
trial will now proceed. This will include a further 54 patients.

This patient cohort will be tracked on either standard
of care versus treatment with CVacTM (CAN-003 is versus
standard of care. CAN-004 is versus placebo.)
The initial patient group, which comprised seven patients
who met the Phase IIb Trial?s eligibility criteria, completed their first injection of the CVacTM vaccine and were then monitored for a period of (at least) 28 days to assess any treatment-related adverse effects.

Prima was delighted to report to the market that this patient group did not suffer any therapy related adverse effects. As a result, the Data Safety Monitoring Board advised that the Phase IIb Trial was safe to proceed.
Its positive verdict was based on a detailed review of
patients? safety laboratory measures of blood, serum and
urine chemistry, vital signs, and any reported study
agent effect.

Further information on the Phase IIb Trial will be released
on the ASX as it becomes available."